Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other Non-Current Assets (2016 - 2025)

Spero Therapeutics' Other Non-Current Assets history spans 10 years, with the latest figure at $153000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $153000.0; the TTM value through Dec 2025 reached $153000.0, changed 0.0%, while the annual FY2025 figure was $153000.0, 0.0% changed from the prior year.
  • Other Non-Current Assets reached $153000.0 in Q4 2025 per SPRO's latest filing, roughly flat from $153000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $5.9 million in Q1 2022 to a low of $153000.0 in Q3 2024.
  • Average Other Non-Current Assets over 5 years is $2.9 million, with a median of $2.8 million recorded in 2021.
  • Peak YoY movement for Other Non-Current Assets: rose 13.76% in 2022, then plummeted 92.44% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $5.6 million in 2021, then grew by 1.7% to $5.7 million in 2022, then tumbled by 92.42% to $435000.0 in 2023, then tumbled by 64.83% to $153000.0 in 2024, then changed by 0.0% to $153000.0 in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Other Non-Current Assets are $153000.0 (Q4 2025), $153000.0 (Q3 2025), and $153000.0 (Q2 2025).